#1 Clinical Trials Search in Europe

Bnt314

BNT314 is an innovative drug currently being studied in clinical trials for patients with advanced or metastatic malignant solid tumors. This article explores the ongoing research, including its safety profile, potential efficacy, and combination therapy with pembrolizumab, an immune checkpoint inhibitor. The trials aim to determine the optimal dosage and evaluate BNT314’s effectiveness in treating various types of advanced cancers.

Table of Contents

What is BNT314?

BNT314 is a new medication being developed to treat advanced or metastatic solid tumors[1]. It is currently being studied in clinical trials to determine its safety and effectiveness. BNT314 is given as an intravenous infusion, which means it’s administered directly into the bloodstream through a vein[1].

How does BNT314 work?

While the exact mechanism of BNT314 is not fully described in the available information, it appears to be a type of immunotherapy. Immunotherapy is a treatment that helps your body’s immune system fight cancer. BNT314 is being studied both alone and in combination with another immunotherapy drug called pembrolizumab[1]. This combination approach suggests that BNT314 may work by enhancing the body’s immune response against cancer cells.

What conditions does BNT314 treat?

BNT314 is being developed to treat advanced or metastatic malignant solid tumors[1]. This term refers to cancers that:

  • Form solid masses in the body (as opposed to blood cancers)
  • Are in an advanced stage, meaning they have grown significantly or spread beyond their original location
  • Are metastatic, which means they have spread to other parts of the body

Current Research on BNT314

BNT314 is currently being studied in a clinical trial that aims to:

  1. Determine the safe dose of BNT314
  2. Evaluate how well it works against advanced solid tumors
  3. Assess its safety when used alone or in combination with pembrolizumab
  4. Understand how the body processes the drug (pharmacokinetics)
  5. Check if the body develops an immune response to the drug (immunogenicity)
[1]

Potential Benefits of BNT314

While it’s important to note that BNT314 is still in the research phase, the study aims to evaluate its potential benefits, including:

  • Shrinking tumors or slowing their growth
  • Improving survival rates for patients with advanced solid tumors
  • Providing a new treatment option for patients who have not responded to or are not eligible for standard therapies
[1]

Safety Considerations

As with any new medication, safety is a primary concern. The clinical trial is designed to carefully monitor for any side effects or adverse reactions. Some specific safety considerations being evaluated include:

  • The occurrence of side effects, including severe or serious ones
  • How the drug affects blood cell counts, liver function, and kidney function
  • Whether the drug interacts with the body’s immune system in unexpected ways
[1]

Who might be eligible for BNT314 treatment?

Currently, BNT314 is only available through clinical trials. Patients who might be eligible for these trials typically:

  • Have advanced or metastatic solid tumors
  • Have tried standard treatments that didn’t work or are not eligible for standard treatments
  • Are in generally good health aside from their cancer
  • Meet specific criteria related to organ function and overall health status
It’s important to note that eligibility criteria can be quite specific and may vary depending on the particular study or treatment phase[1].

If you think BNT314 might be an option for you or a loved one, it’s crucial to discuss this with your oncologist. They can provide more information about current clinical trials and whether you might be eligible to participate.

Aspect Details
Drug Name BNT314
Administration Intravenous infusion
Target Condition Advanced or metastatic malignant solid tumors
Trial Phase First-in-human, dose escalation with expansion cohorts
Main Objectives Determine MTD, RP2D, safety profile, and preliminary efficacy
Combination Therapy BNT314 with pembrolizumab (immune checkpoint inhibitor)
Key Endpoints Safety, ORR, DCR, DOR, PFS, OS
Eligibility Adults with advanced solid tumors, adequate organ function, ECOG 0-1

FAQ

  • What is BNT314? BNT314 is an investigational drug being studied for the treatment of advanced or metastatic malignant solid tumors. It is administered as a solution for intravenous infusion.
  • What is the main goal of the BNT314 clinical trial? The main goal is to determine the maximum tolerated dose, establish the recommended dose for phase II, and evaluate the safety and preliminary efficacy of BNT314 alone and in combination with pembrolizumab in patients with advanced solid tumors.
  • Who is eligible to participate in the BNT314 clinical trial? Eligible participants are adults (18 years or older) with histologically confirmed advanced malignant solid tumors who have experienced disease progression on or after standard therapy, or were intolerant of or not eligible for standard therapy.
  • What are some of the key inclusion criteria for the trial? Key inclusion criteria include having measurable disease according to RECIST v1.1, adequate organ function, life expectancy of more than 3 months, and an ECOG performance score of 0 or 1.
  • How is the effectiveness of BNT314 being measured in the trial? The effectiveness is being measured through various endpoints, including objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) based on tumor assessments according to RECIST 1.1 criteria.

Ongoing Clinical Trials on Bnt314

  • Study of BNT314 and BNT327 with chemotherapy for patients with metastatic colorectal cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Germany Spain

  • Study on the Safety and Effects of BNT314 Alone or with Pembrolizumab for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium Denmark Spain

Glossary

  • Advanced or metastatic malignant solid tumors: Cancers that have spread from their original location to other parts of the body or have grown significantly, making them difficult to treat.
  • Immune checkpoint inhibitor: A type of drug that helps the immune system recognize and attack cancer cells more effectively.
  • Pembrolizumab: An immune checkpoint inhibitor used in combination with BNT314 in some parts of the trial.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Recommended dose for phase II (RP2D): The dose of the drug determined to be safe and potentially effective for further testing in larger clinical trials.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Disease control rate (DCR): The percentage of patients whose cancer shrinks, disappears, or remains stable after treatment.
  • Duration of response (DOR): The length of time that a tumor continues to respond to treatment without growing or spreading.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without their cancer progressing.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.
  • Dose-limiting toxicity (DLT): Side effects that are severe enough to prevent an increase in the dose of a drug during a clinical trial.
  • ECOG performance score: A scale used to assess a patient's level of functioning and ability to care for themselves, ranging from 0 (fully active) to 5 (dead).

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-bnt314-alone-or-with-pembrolizumab-for-patients-with-advanced-solid-tumors/